GeneCentric Therapeutics
Latest round
- Series C
Last raised
- Jun 2025
Total raised
- $15M
Investors
- 4
About GeneCentric Therapeutics
GeneCentric Therapeutics, Inc. is a biotechnology firm focused on advancing precision oncology through innovative liquid biopsy technology that integrates gene expression analysis with circulating tumor DNA sequencing. Founded in 2011 and headquartered in Durham, North Carolina, GeneCentric Therapeutics, Inc. specializes in developing technologies for cancer diagnostics. In June 2025, GeneCentric Therapeutics, Inc. GeneCentric specializes in advanced liquid biopsy technology that combines gene expression analysis with standard circulating tumor DNA (ctDNA) sequencing. Their flagship product, the ExpressCT™ technology, is integrated within the GenomicsNext™ platform, enabling precise detection of DNA alterations and gene expression, thus providing a comprehensive solution for precision cancer treatment.GeneCentric generates revenue through partnerships and direct transactions with clients in the biopharma and research sectors. Their revenue model includes collaborations and licensing agreements that grant clients access to proprietary technologies such as the ExpressCT™ platform and GenomicsNext™ services. These agreements often involve service contracts for advanced genomic profiling and biomarker analysis, supporting innovative cancer treatment research.
Who invested in GeneCentric Therapeutics
4 investors across 5 rounds
See all investors in GeneCentric Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about GeneCentric Therapeutics
Who invested in GeneCentric Therapeutics?
GeneCentric Therapeutics has 4 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has GeneCentric Therapeutics raised?
GeneCentric Therapeutics has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did GeneCentric Therapeutics last raise money?
GeneCentric Therapeutics's most recent round on record is a Series C, in Jun 2025.
What does GeneCentric Therapeutics do?
GeneCentric Therapeutics is a biotechnology company.
Where is GeneCentric Therapeutics headquartered?
GeneCentric Therapeutics is headquartered in Durham, US.
Which VCs invest in companies like GeneCentric Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at GeneCentric Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like GeneCentric Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.